Introduction
Between September 2003 and December 2009, the ENRY (European Network on Radioembolisation with Yttrium-90 resin microspheres) group collated data on 325 consecutive patients with a confirmed diagnosis of hepatocellular carcinoma (HCC) who received selective internal radiation therapy (SIRT), also known as radioembolisation, with yttrium-90 ( The ENRY study population had primarily good liver function (Child-Pugh class A; 82.5%), underlying cirrhosis (78.5%) and Eastern Cooperative Oncology Group (ECOG) performance status (ECOG 1; 45.7%). Many had multinodular disease (75.9%), invading both lobes (53.1%) including some with high alpha-fetoprotein (>400 ng/mL; 34.9%), PVT (23.3%) and EHD (9.2%). Most patients (93.2%) received SIRT as a single procedure (median activity administered 1.6 GBq) and were followed-up for a median of 10.0 months.
Safety and tolerability
ENRY provides a comprehensive analysis of the safety and tolerability of SIRT in a cohort with a high incidence of cirrhosis. 1 Patients were assessed for procedurerelated adverse events up to 7 days post-SIRT and thereafter, for radiation-related adverse events up to 3 months. Overall, there was a low incidence of mainly mild, transient post-procedural adverse events (Table 1) . 1 The incidence of radiation-related events was generally unremarkable except for an increase in the proportion of patients with raised bilirubin levels compared with the pretreatment assessment ( Table 2) . 
Survival
Median survival was 13.1 months (95% confidence interval [CI] 10.9-15.8) and varied significantly by Barcelona Clinic Liver Cancer (BCLC) stage (Fig. 1) .
Is age a limitation for SIRT?
In patients stratified by age (<70 yrs or 70 yrs), median survival (95% CI) was similar regardless of age: 12.8 months (10.8-17.9) vs 14.5 months (10.6-16.8), respectively in each group (p = 0.942).
1 SIRT was equally well tolerated in both populations.
Is SIRT suitable for Child-Pugh B patients?
Reduced functional reserve and impaired regenerative ability of the cirrhotic liver increase the risk of liver failure, especially for patients who have had prior extensive resection, or liver insult from toxins, acute viral hepatitis or external irradiation. In the ENRY analyses, patients receiving SIRT with Child-Pugh B had a shorter median survival (95% CI) than patients with Child-Pugh A: 10.0 months (6.1-13.8) vs. 14.9 months (11.9-17.1); p = 0.006. Key factors, such as the presence of ascites, were thought to contribute to the lower survival with SIRT: median survival (95% CI) with and without ascites: 6.1 months (4.4−8.6) vs. 14.1 months (11.8-17.9); p < 0.001.
How does SIRT compare with transarterial chemoembolisation (TACE) in intermediate-stage HCC?
Typical More than half the candidates (56.3%) for SIRT from the ENRY study had advanced-(BCLC) stage C HCC due to the presence of either vascular invasion, EHD or altered cancer-related performance status.
Median survival in this subset was 10.0 months (95% CI 7.7-10.9) and treatment was well-tolerated, although fatigue (mostly mild grade 1 events) was more common in patients with deteriorating ECOG performance status. 4 Investigators found that SIRT was as effective and equally well tolerated in patients with and without PVT without any significant reduction in overall survival or increased risk of laboratory parameter adverse events. 4 It is notable that comparisons of the populations from the ENRY and sorafenib studies include a very similar population of patients with mixed intermediate-and advanced-stage HCC, 5 although the studies of sorafenib tended to include a higher percentage of patients with EHD, particularly in the Asia-Pacific trial 6 . Even so, 58%
(189 of 325) of patients from the ENRY cohort matched the inclusion criteria for the SHARP trial. Analyses of these cohorts found a significant overlap in terms of overall survival between the two treatment modalities, 7 with a median overall survival with SIRT of 10.8 months (95% CI: 8.8-12.8) in SHARP-equivalents and 10.2 months (95% CI: 8.3-11.8) in a subset of these patients with PVT or EHD. Studies are ongoing to evaluate the relative safety and efficacy of these two treatments either in combination or as monotherapies.
Conclusion
SIRT appears to be a particularly promising treatment in cohorts who may not otherwise be considered for locoregional therapy, i.e. patients with intermediatestage HCC who are poor candidates for TACE (bilobar and/or multiple tumours) and/or have failed prior TACE/TAE, or patients with advanced-stage HCC, particularly those with PVT. Further prospective evaluations of the clinical benefit for SIRT in these patient populations are warranted.
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